Compassionate Use of Tetrabenazine in the Treatment of Hyperkinesias
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
详细描述
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
- •Willing to sign informed consent.
- •Willing to comply with procedures required as part of this study.
排除标准
- •Those subjects unwilling to comply with study requirements.
- •Subjects unable to give informed consent.
研究者
Joseph Jankovic
Professor, Neurology-PDCMDC
Baylor College of Medicine